SCOTUS Backs Hikma Skinny-Label Win on Vascepa; ADC Therapeutics Crashes 50% on Death

The Supreme Court just handed the generics industry a unanimous win — Hikma's skinny-label Vascepa doesn't infringe Amarin's patents, and that decision reshapes the legal calculus for every carved-out generic launch in the country.

Meanwhile, ADC Therapeutics loses half its market cap on a death rate the Street says may be insurmountable, Legend Biotech sparks an in vivo CAR-T rally, and biotech M&A blows past $106 billion year-to-date. Packed Thursday.

Welcome to The Pharma Closeout for Thursday, June 4th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

The top story — the U.S. Supreme Court ruled unanimously in favor of Hikma Pharmaceuticals. Justice Jackson wrote the opinion, holding that Amarin failed to plausibly allege Hikma actively induced infringement of its Vascepa patents. This is the skinny-label case the generics industry has been bracing for — and it's now precedent.

What this does is validate the entire legal architecture of skinny labeling. A generic maker can carve out patented indications, launch with only the off-patent uses on the label, and the brand can no longer simply argue that doctors will prescribe it off-label for the patented use and call that inducement. Amarin tried exactly that theory, and all nine justices rejected it.

And Hikma is moving fast. The company just committed substantial capital to expand its Ohio manufacturing facilities in Columbus and Bedford, creating a significant number of new jobs. That's a company investing in domestic generics capacity on the same day the Court validates the legal framework that capacity depends on.

I'd push back slightly on the idea that this immediately accelerates every generic launch in the pipeline. The ruling protects skinny-label filers from inducement claims, but it doesn't change the Paragraph IV landscape or REMS barriers. Where this really bites is the revenue tail on branded multi-indication drugs. Companies relying on method-of-use patents as a second line of defense after composition-of-matter expiry just lost significant leverage.

Fair — but the cumulative effect still compresses timelines. Every generic company's legal team just got a unanimous Supreme Court citation to put in their next ANDA filing strategy memo. The risk-adjusted return on skinny-label launches just improved materially.

And payers will feel this before anyone else. The moment generic entry timelines shorten, the branded pricing window narrows — and managed care formulary committees will start modeling that compression into their contracting cycles.

That pricing compression plays directly into the deal story, and shifting to the deal side, the macro number is striking. Per PitchBook data published by CNBC today, biotech M&A has hit $106 billion across 201 transactions so far in 2026. Average deal value: $527.3 million, up sharply from $365 million in 2025. For trajectory — 2024 came in at $114.8 billion total, 2025 hit $209 billion, and if this pace holds, 2026 crosses $250 billion. That would be the strongest year since the 2019 peak. Let's bring in Marcus Webb on this one.

HSBC's Rajesh Kumar put it bluntly — pharma companies are "really buying stuff like it's going out of fashion." And that momentum persists despite the worsened interest rate environment from inflationary pressures. Now, on the pipeline side — two clinical stories heading in opposite directions. ADC Therapeutics saw its stock crater more than 50% after Phase 3 LOTIS-5 data for Zynlonta in relapsed or refractory DLBCL. The trial enrolled a substantial patient population. The Zynlonta-rituximab combination met its primary endpoint — significantly improved progression-free survival, higher overall and complete response rates versus the control. But the safety signal buried everything: a notably higher death rate in the treatment arm compared to the control arm, raising serious concerns.

That's a confirmatory trial. LOTIS-5 was the path from accelerated to full approval. When your confirmatory study shows the drug works but also shows a nearly three-fold mortality differential, the FDA isn't reviewing a supplemental filing — they're revisiting whether the original risk-benefit determination still holds. The accelerated approval itself is now exposed.

On the other end of the spectrum — Legend Biotech surged on early data from its in vivo CAR-T program in lymphoma. All recipients showed reduced or eliminated disease signs.

So what does it cost to manufacture an ex vivo CAR-T today versus what an in vivo approach could eventually deliver? That's the question that matters most here. Per-patient manufacturing for current therapies runs into the hundreds of thousands before the drug even reaches the patient. If in vivo engineering achieves comparable durability while collapsing vein-to-vein time and the manufacturing chain, it doesn't just compete with Novartis's Kymriah — it restructures the entire cell therapy cost curve.

Four more quick items. Alnylam signed its first AI discovery deal with RNA specialist Inceptive — potentially worth $2 billion. Parabilis Medicines filed for a $413 million IPO to back its peptide pipeline — that would be the twelfth biotech listing of 2026. Fulcrum Therapeutics is exploring a sale after the FDA sidelined its sickle cell program — another small-cap pivoting to exit when the regulatory path closes. And Celcuity's breast cancer drug fell short of what analysts called lofty expectations in an ASCO-spotlighted trial — conference season cuts both ways. The deal and data pipeline tells you where conviction is concentrating: next-generation modalities, AI-augmented discovery, and strategic exits when the thesis breaks.

On the regulatory side, three items to triage. Lead story — Novo Nordisk's facility in Indiana, the former Catalent site, is under FDA scrutiny again. A re-inspection in April found mammalian hair in finished drug product and water leaks from the roof. These are repeat contamination findings at a facility Novo has been trying to remediate since the acquisition.

And the timing is brutal. Every quality hold at that site becomes a supply bottleneck at exactly the moment Novo needs maximum GLP-1 throughput. The demand curve does not wait for remediation timelines.

Second — acting FDA Commissioner Kyle Diamantas said publicly he's not interested in the permanent role. He met with executives from 15 rare disease nonprofits this week and pledged to prevent political interference in regulatory decisions — a deliberate break from the Makary era. The signal is constructive, but it also means the agency is operating under extended interim leadership during a period of heavy PDUFA activity.

That leadership vacuum matters more than most people realize when you're looking at how the agency prioritizes advisory committee scheduling and review team resources.

And the batch. Otsuka presented new data showing Voyxact preserved kidney function over an extended follow-up period in IgA nephropathy as it pursues conversion from accelerated to full approval. Twelve months of eGFR preservation is encouraging, but the FDA will want to see whether that slope holds through a longer observation window before converting — the bar for full approval in IgAN is still being defined in real time. Separately, Cingulate received a Complete Response Letter for its ADHD drug CTx-1301 — the PDUFA target had been May 31st. And Axsome locked out generic competitors to its narcolepsy drug Sunosi through 2040 via settlement — which, on the same day the Supreme Court strengthens skinny-label rights, is a useful reminder that patent strategy is a many-front war. The throughline across all of this: the FDA is processing a massive caseload under interim leadership, and the quality of those outputs — from manufacturing inspections to approval conversions — deserves closer scrutiny.

What to watch. June 19th — PDUFA date for Merck's WELIREG plus KEYTRUDA combination in adjuvant renal cell carcinoma. We flagged this earlier in the week. Merck spent ASCO building the cornerstone therapy narrative around this combination, and June 19th either validates that positioning or forces a recalibration.

And June 11th, EHA 2026 opens. We've been tracking Legend Biotech's LB2501 data for the late-breaking slate — after today's in vivo news, their full hematology program draws even sharper attention. Also keep an eye on the COINS Act — the House bill that would add biotechnology to the investment restriction framework targeting China. Pfizer and Bristol Myers were both named in connection with recent Chinese biotech deals. Given the M&A velocity Marcus described, any legislative movement there redraws the deal map for the entire second half.

That is your Pharma Closeout for Thursday. The Supreme Court reshaping skinny-label law for Hikma and every generics maker behind them, ADC Therapeutics facing an existential safety question on Zynlonta, Legend Biotech opening a new chapter for in vivo cell therapy, and a $106 billion M&A market showing no signs of cooling — this industry does not take days off. If this briefing saves you time, follow us on Spotify and drop a rating — it helps other pharma professionals find the show. We'll be back tomorrow.

Have a good evening. See you tomorrow. ## EPISODE METADATA **Title:** SCOTUS Backs Hikma Skinny-Label Win on Vascepa; ADC Therapeutics Crashes 50% on Zynlonta Deaths; Biotech M&A Hits $106B | Jun 04, 2026 **Description:** SCOTUS unanimously backs Hikma's skinny-label Vascepa generic, reshaping patent defense for branded pharma. ADC Therapeutics drops 50%+ on LOTIS-5 death rate (13.2% vs 4.6%), biotech M&A crosses $106B in 2026, and Legend Biotech surges on in vivo CAR-T data. **Tags:** Hikma, Amarin, Vascepa, skinny label, Supreme Court, generics, ADC Therapeutics, Zynlonta, loncastuximab tesirine, DLBCL, LOTIS-5, Legend Biotech, CAR-T, in vivo, Novo Nordisk, FDA, manufacturing, Kyle Diamantas, Merck, WELIREG, KEYTRUDA, Alnylam, Inceptive, Parabilis, Fulcrum, Celcuity, Axsome, Sunosi, biotech M&A, COINS Act, Otsuka, Voyxact, IgA nephropathy, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #